SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk - Takeaways - MDSpire

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

A Korean cohort study found fewer kidney cancer cases among patients with type 2 diabetes who initiated sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors.

  • By

  • Andrea Surnit

  • June 9, 2026

  • 5 min

Share

  • 1

    SGLT2 inhibitors are associated with a lower incidence of kidney cancer compared to DPP-4 inhibitors in patients with type 2 diabetes.

  • 2

    The study involved 57,103 users of SGLT2 inhibitors and 57,103 users of DPP-4 inhibitors, with a follow-up of approximately 3.5 years.

  • 3

    SGLT2 inhibitor users had a 40% lower hazard of kidney cancer, with an incidence rate of 18.9 cases per 100,000 person-years.

  • 4

    The findings suggest potential mechanisms for reduced kidney cancer risk, but these were not directly tested in the study.

  • 5

    Limitations include observational design, short follow-up, and lack of individual agent data, affecting generalizability and potential confounding.

Original Source(s)

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

  • by Andrea Surnit

  • June 9, 2026

Related Content

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Cardiac and aerobic response to growth hormone therapy in children with short stature: a prospective study using VO2max and speckle tracking echocardiography

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.